Royalty Pharma (RPRX) Invested Capital (2019 - 2026)

Royalty Pharma has disclosed Invested Capital across 8 years of filings, most recently posting $18.9 billion for Q1 2026.

• Invested Capital for Q1 2026 came in at $18.9 billion, up 8.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.9 billion (up 8.61% YoY), and the FY2025 annual result was $18.7 billion, up 3.96% from the prior year.
• Invested Capital came in at $18.9 billion for Q1 2026 at Royalty Pharma, up from $18.7 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $18.9 billion in Q1 2026 to a low of $15.7 billion in Q3 2023.
• The 5-year median for Invested Capital is $17.4 billion (2025), against an average of $17.3 billion.
• Across the five-year window, Invested Capital declined 10.33% in 2023 and advanced 13.68% in 2024, its largest moves.
• Royalty Pharma's Invested Capital stood at $16.6 billion in 2022, then dropped by 2.54% to $16.2 billion in 2023, then climbed by 10.7% to $18.0 billion in 2024, then rose by 3.96% to $18.7 billion in 2025, then climbed by 1.22% to $18.9 billion in 2026.
• The last three Invested Capital figures came in at $18.9 billion (Q1 2026), $18.7 billion (Q4 2025), and $18.6 billion (Q3 2025), per Business Quant data.